Alpha Teknova, Inc. (TKNO) Stock Price & Analysis
Alpha Teknova, Inc. (TKNO) fell 4.42% to USD 4.97 as of July 25, 2026 at 19:05 UTC, according to Nexqual real-time market data.
TKNO last closed at USD 5.2; the session ranged USD 4.8–5.2 on volume of 129,059 shares. Market capitalization is $266.46M, with a 52-week range of USD 1.91–6.68 (NGM). Source: Nexqual, July 25, 2026 at 19:05 UTC.
Key Statistics (as of July 25, 2026 at 19:05 UTC)
| Price | USD 4.97 |
|---|---|
| Change | ▼ 4.42% (down) |
| Previous Close | USD 5.2 |
| Open | USD 5.2 |
| Day Range | USD 4.8 – 5.2 |
| 52-Week Range | USD 1.91 – 6.68 |
| Volume | 129,059 shares |
| Market Cap | $266.46M |
| Exchange | NGM |
Technical Analysis (TKNO)
Nexqual's technical model rates TKNO "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 19:05 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 44.23 (neutral) |
| vs SMA50 | Above (USD 4.88) |
| MACD | 0.07 (positive) |
Analyst Ratings (TKNO)
Wall Street analysts rate TKNO "Buy" based on 3 analysts, with a mean price target of USD 9 (range USD 7–12), per Nexqual as of July 25, 2026 at 19:05 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 9 |
| High Target | USD 12 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 4 / 2 / 0 |
Earnings (TKNO)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $10.91M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.09 ▲ beat |
| 2025-12-31 | USD -0.09 vs est -0.09 ▲ beat |
| 2025-09-30 | USD -0.08 vs est -0.09 ▲ beat |
| 2025-06-30 | USD -0.07 vs est -0.1 ▲ beat |
Source: Nexqual, July 25, 2026 at 19:05 UTC.
Financials & Fundamentals (TKNO)
| Total Revenue | $41.80M |
|---|---|
| Revenue Growth (YoY) | +13.10% |
| Gross Margin | +34.01% |
| Operating Margin | -38.80% |
| Profit Margin | -41.07% |
| ROE | -23.92% |
| Debt / Equity | 42.86 |
| Current Ratio | 4.59 |
| Total Cash | $17.78M |
| Total Debt | $27.83M |
| Free Cash Flow | $-2.39M |
Source: Nexqual, July 25, 2026 at 19:05 UTC.
Financial Health Score (TKNO)
Nexqual rates Alpha Teknova, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 19:05 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $18M cash vs $28M debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Critical — ROE -24%, ROA -9.3% |
Ownership (TKNO)
| Insider Ownership | +9.32% |
|---|---|
| Institutional Ownership | +84.67% |
| Shares Outstanding | 53.61M |
| Float | 10.88M |
| Short % of Float | +14.43% |
Source: Nexqual, July 25, 2026 at 19:05 UTC.
Leadership (TKNO)
Alpha Teknova, Inc. is led by Stephen Gunstream (age 45), President, CEO & Director, per Nexqual as of July 25, 2026 at 19:05 UTC.
| President, CEO & Director | Stephen Gunstream (age 45) |
|---|---|
| Chief Financial Officer | Matthew C. Lowell (age 54) |
| Senior Vice President of Marketing | Jennifer Henry |
Major Backers & Investors (TKNO)
Notable institutional backers of Alpha Teknova, Inc. include Roubaix Capital, LLC, Royce & Associates LP, ROYCE MICRO-CAP TRUST, INC.-Royce Micro-Cap Trust Inc, according to Nexqual as of July 25, 2026 at 19:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Roubaix Capital, LLC | 3.51% |
| Royce & Associates LP | 1.99% |
| ROYCE MICRO-CAP TRUST, INC.-Royce Micro-Cap Trust Inc | 1.23% |
| Millennium Management | 0.83% |
| UBS Group AG | 0.61% |
| Conestoga Capital Advisors, LLC | 0.59% |
| ROYCE FUND-Royce Micro-Cap Fund | 0.57% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.11% |
| Vanguard Group | 1.64% |
| Geode Capital | 0.57% |
Source: Nexqual, July 25, 2026 at 19:05 UTC.
From Alpha Teknova, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
- The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
- It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
- The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RLYB | Rallybio Corporation | USD 16.31 | ▼ 1.87% |
| TARA | Protara Therapeutics, Inc. | USD 4.02 | ▼ 1.47% |
| SERA | Sera Prognostics, Inc. | USD 2.05 | ▼ 1.44% |
| TCRX | TScan Therapeutics, Inc. | USD 0.79 | ▼ 11.78% |
| IPSC | Century Therapeutics, Inc. | USD 2.11 | ▼ 1.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 19:05 UTC. This page is informational and not investment advice.